



## Original Research Article

# Antibiotic Susceptibility Pattern of Uropathogens Isolated in a Rural Teaching Hospital in South India

P. Lakshmi Vasantha\* and K. Sai Leela

Department of Microbiology, Kamineni Institute of Medical Sciences,  
Narketpally, Nalgonda Dt., Telangana state, India

\*Corresponding author

## ABSTRACT

Urinary tract infection is one of the most common infections encountered and is of major public health importance. Because of development of antibiotic resistance, the susceptibility pattern of uropathogens to commonly prescribing drugs varying from time to time. The present study was conducted to know the current susceptibility pattern of uropathogens from both community acquired and hospital acquired urinary tract infections. Out of 1350 urine samples from hospitalized patients and 742 samples from out patients 322(23.85%), and 148 (19.94%) showed significant growth respectively. *Escherichia coli* was the predominant uropathogen isolated from both hospitalized patients (66.45%) and out patients (70.27%). Other organisms isolated were *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Acinetobacter* species, *Citrobacter* species, *Proteus mirabilis*, *Enterobacter* species, *Enterococcus* species and *Staphylococcus aureus*. Predominant uropathogens like *E. coli* and *Klebsiella pneumoniae* were resistant to commonly used antibiotics like Norfloxacin, Ampicillin and Cotrimoxazole. 74%, 52%, 88% of *E. coli* from hospitalized patients and 62%, 39%, 80% from out patients showed resistance to Norfloxacin, Cotrimoxazole and Ampicillin respectively. Common uropathogen *E. coli* had shown good susceptibility pattern to drugs like Nitrofurantoin (78%, 81%), Amikacin (79%, 100%) and to Imipenem (91%, 100%) in hospitalized and out patients respectively. Extended spectrum  $\beta$  lactamase production by Gram negative bacilli and increased empirical use of Quinolones for treatment of UTI is mainly responsible for development of drug resistance to  $\beta$  lactam antibiotics and Quinolones.

## Keywords

Uropathogens,  
Current  
antibiotic  
susceptibility  
pattern, Drug  
resistance

## Introduction

Urinary tract infection is one of the most common infections observed in clinical

practice among community and hospitalized patients (Gatermann, 2007). 25 to 35% of all

females suffer from urinary tract infection (UTI) at some stage in their lives. UTI forms 40–50% of the total nosocomial infections. Urinary tract infection often results in serious complications like secondary bacteremia and sepsis leading to a rise in mortality. Extremities of age, female gender, pregnancy, instrumentation, neurological dysfunction, renal disease, expression of A, B and H blood group oligosaccharides on the surface of epithelial cells are the predisposing factors for the development of UTI. Treatment of UTI depends on etiological agents and their antibiotic susceptibility pattern. As susceptibility pattern is varying because of development of drug resistance in uropathogens, it became necessary for physicians to have current knowledge about antibiotic susceptibility pattern (Manjunath *et al.*, 2011; Kumar *et al.*, 2006). This study was conducted to know the current antibiotic susceptibility pattern in common uropathogens isolated in a rural teaching hospital in south India.

## Material and Methods

This study was conducted in department of Microbiology, in a rural teaching hospital in south India from May 2014 to March 2015. Clean catch midstream urine (CCMU) were collected from ambulatory patients and from Foley's catheter in catheterized patients. All samples were inoculated on blood agar and Mac Conkeys medium by using calibrated loop technique. Urine microscopy was done to see pus cells. In mid-stream urine samples,  $>10^5$  colony forming units per ml (CFU/ml) of urine was considered as significant bacteriuria. Identification of growth was done by standard biochemical methods (Collee *et al.*, 1999). The antibiotic susceptibility testing was carried out by using Kirby-Bauer disc diffusion method following guidelines of Clinical Laboratory Standard Institute (CLSI). Extended spectrum  $\beta$  lactamase

production in Gram negative bacilli and Methicillin resistance in *Staphylococcus aureus* was detected by using CLSI guide lines (CLSI, 2014).

## Results and Discussion

A total of 1350 urine samples from hospitalized patients and 742 from out patients were collected. Among hospitalized patients 322 (23.85%) showed significant growth. 810(60%) samples were sterile. 35(2.59%) samples showed insignificant growth and 183 (13.55%) were polymicrobial. Among out patients 148 (19.94%) showed significant growth, 497(66.98%) samples were sterile. 18 (2.4%) showed insignificant growth and 79(10.64%) were contaminated.

In hospitalized patients, out of 322 culture positive samples, Gram negative bacilli (94.40%) were predominate over Gram positive (5.99%). *Escherichia coli* (66.45%) was the predominant etiological agent isolated. Other Gram negative bacilli isolated were *Klebsiella* species 51(15.84%), *Pseudomonas aeruginosa* 16(4.96%), *Acinetobacter* species 9(2.79%), *Citrobacter* species 8(2.48%), *Proteus mirabilis* 5(1.55%), *Enterobacter* species 1(0.31%). Among Gram positive isolates *Enterococcus* species 12(3.72%) was predominant followed by *Staphylococcus aureus* 6(1.86%).

In outpatients also *E. coli* was the predominant organism 104(70.27%) followed by *Klebsiella pneumoniae* 44(29.72%).

In hospitalized patients, females 256 (79.50%) were infected more commonly compared to males 66 (20.49%). Among females, reproductive age group 21–30 years women (42.57%) were predominantly infected compared to other age groups.

Among men age group above 60 years were infected more 16(24.24%) compared to other age groups. In outpatients also females were infected more 105(71%) compared to males 43(29%).

In hospitalized patients eighty eight percent of *E. coli* isolates were resistant to Ampicillin. The rates of resistance among Gram negative bacilli to cephalosporins including 3<sup>rd</sup> generation were increasingly high. Ceftazidime resistance in *E. coli* was 80% and in *Klebsiella* species it was 82%. Among non-fermenters 58% of *Pseudomonas aeruginosa*, 58% of *Acinetobacter* species, 75% of *Proteus* species were resistant to ceftazidime. In outpatients also *E. coli* showed 80% resistance to Ampicillin. 57% of *E. coli* isolates and 50% of *Klebsiella pneumoniae* were resistant to Ceftazidime.

Resistance to quinolones was increased among Gram negative bacilli isolated from hospitalized patients and outpatients also. 74% of *E. coli*, 50% *Klebsiella* species, 59% *Pseudomonas aeruginosa*, 72% *Acinetobacter* species isolated from hospitalized patients showed resistance to Norfloxacin. In outpatients 62% of *E. coli* and only 10% of *Klebsiella pneumoniae* were resistant to Norfloxacin.

Coming to the aminoglycoside susceptibility pattern in Gram negative bacilli isolated from hospitalized patients, 42% and 21% of *E. coli* were resistant to Gentamicin and Amikacin respectively. 40% and 27% of *Klebsiellae* species isolates were resistant to Gentamicin and Amikacin. Among nonfermentors 10% of *Pseudomonas aeruginosa* strains were resistant Amikacin and 27% were resistant to Gentamicin. 25% of *Acinetobacter* species strains were resistant to both Gentamicin and Amikacin.

In outpatients 80% of *E. coli* and 82% of *Klebsiella pneumoniae* were susceptible to Gentamicin. All isolates were sensitive to Amikacin.

In hospitalized patients 78% strains of *E. coli* were sensitive (22% resistant) to Nitrofurantoin. But only 33% strains of *Klebsiella* species were sensitive to Nitrofurantoin. In outpatients 81% of *E. coli* and 36% of *Klebsiella pneumoniae* were sensitive to Nitrofurantoin.

Resistance to cotrimoxazole was varied in out patients and inpatients. 52% and 56% of *E. coli* and *Klebsiella pneumoniae* strains from hospitalized patients showed resistance. But in out patients 39% of *E. coli* and 40% *Klebsiella pneumoniae* strains were resistant. 33% resistance was observed in *Acinetobacter* species.

From hospitalized patients ESBL production in Gram negative bacilli was 238 (68.32%). 80% of *E. coli*, 82% of *Klebsiella* species, 58% of *P. aeruginosa* & *Acinetobacter* species each were ESBL producers. In outpatients ESBL production among *E. coli* and *Klebsiella pneumoniae* was 57% and 50% respectively.

Resistance to Imipenem was observed in 9% of *E. coli* & 11% of *Klebsiella pneumoniae* from hospitalized patients. In outpatients all isolates of *E. coli* and *Klebsiella pneumoniae* were sensitive to Imipenem.

Among Gram positive isolates 75% *Staphylococcus aureus* isolates were Methicillin resistant (MRSA). But all isolates were sensitive to Cotrimoxazole, Nitrofurantoin and Vancomycin. 80% of strains were resistant to Norfloxacin. Among *Enterococcus* species 40%, 65%, 80% strains were resistant to Nitrofurantoin,

Ampicillin and Norfloxacin respectively. But all were sensitive to Vancomycin.

Present study showed that females were more commonly infected with urinary tract infections compared to males both in hospitalized (79.50%) and outpatients (71%). Male to female ratio was 3.8:1 in hospitalized patients and in outpatients it was 2.44:1. This was in correlation with other studies (Akram *et al.*, 2007; Ram *et al.*, 2000). Among females 21–30 years age group predominantly was infected (42.57%). But in males age group above 60 years were infected more 16 (24.24%). The predominance of UTI in female population is because of short urethra and proximity of anal opening to urethra.

In the present study Gram negative bacilli were the common agents to cause UTI compared to Gram positive organisms and *E. coli* was the predominant organism in both hospitalized patients (66.45%) and outpatients (70.27%). This was also observed in other studies also (Manjunath *et al.*, 2011; Ram *et al.*, 2000; Dalela *et al.*, 2012). Other Gram negative bacilli isolated from hospitalized patients were *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Acinetobacter* species, *Citrobacter* species, *Proteus mirabilis* and *Enterobacter* species (Bhargavi *et al.*, 2010). Other organism isolated from out patients was *Klebsiella pneumonia* (29.72%).

Our study shows predominant Gram negative bacilli to cause UTI in both hospitalized and outpatients like *E. coli* and *Klebsiella pneumoniae* were resistant to commonly used antibiotics like Norfloxacin, Cotrimoxazole and Ampicillin. This was observed in other studies (Manjunath *et al.*, 2011; Arjunan *et al.*, 2010; Mohanty *et al.*, 2013). Resistance to these antibiotics in hospitalized patients was high compared to

out patients. 74%, 52 & 88% of *E. coli* from hospitalized patients and 62%, 39%, 80% from outpatients showed resistance to norfloxacin, cotrimoxazole & ampicillin. Cephalosporins including 3<sup>rd</sup> generation showed high resistance pattern in both hospitalized patients and outpatients. Extended spectrum  $\beta$  lactamase production by *E. coli* & *Klebsiella pneumoniae* and other Gram negative bacilli is responsible for resistance to cephalosporins. Wide spread use of quinolones in treatment of UTI may be responsible for increasing resistance to quinolones in Gram negative bacilli. This was observed in other studies (Zervos *et al.*, 2003; Ena *et al.*, 1995). In our study ESBL producing Gram negative bacilli were 68.32%. 80% of *E. coli* & 82% of *Klebsiella pneumoniae* from hospitalized patients were ESBL producers. Decreased sensitivity to Cotrimoxazole was observed in the present study. *E. coli* and *Klebsiella pneumoniae* isolated from out patients had showed 61% and 60% sensitivity but from hospitalized patients shown only 48% and 44% sensitivity to Cotrimoxazole.

To our surprise 78% of strains of *E. coli* from hospitalized patients and 81% of *E. coli* from out patients were sensitive to Nitrofurantoin which was not prescribed that much frequently by clinical practitioners. This was also observed in some studies (Mandal *et al.*, 2012). But resistance to Nitrofurantoin was high in *Klebsiella pneumoniae*, only 33% and 36% of strains were sensitive from hospitalized and out patients respectively.

Resistance to aminoglycosides is comparatively less in Gram negative bacilli and 79% of strains of *E. coli*, 73% of *Klebsiella pneumoniae*, 90% of *Pseudomonas aeruginosa* and 75% of *Acinetobacter* species from hospitalized patients and 100% of *E. coli* and *Klebsiella pneumoniae* from

out patients were sensitive to Amikacin. Even sensitivity to Gentamicin was also significant in *E. coli* and *Klebsiella pneumoniae* isolated from out patients i.e. 80% and 82%. This was in correlation with

other studies (Mandal *et al.*, 2012). But only 58% of *E. coli* and 60% of *Klebsiella pneumoniae* from inpatients were sensitive to Gentamicin.

**Table.1** Age and sex wise distribution of inpatients

Age group	Sex distribution		Total
	Male	female	
0-10	11 (3.42%)	10(3.10%)	21 (6.52%)
11-20	6(1.86%)	55(17.08%)	61(18.94%)
21-30	11(3.42%)	109(33.85%)	120(37.27%)
31-40	7(2.17%)	29(9.00%)	36(11.17%)
41-50	6(1.86%)	28(8.69%)	34(10.55%)
51-60	9(2.79%)	18(5.59%)	27(8.38%)
61-70	16(4.96%)	7(2.17%)	23(7.14%)
Total	66(20.49%)	256 (79.50%)	322(100%)

**Table.2** Etiological agents isolated from hospitalized patients

Bacterial species	Total number
<i>E.coli</i>	214(66.45%)
<i>Klebsiella pneumoniae</i>	51(15.84%)
<i>Pseudomonas aeruginosa</i>	16(4.96%)
<i>Citrobacter species</i>	8 (2.48%)
<i>Acinetobacter species</i>	9 (2.79%)
<i>Proteus mirabilis</i>	5 (1.55%)
<i>Enterobacter species</i>	1 (0.31%)
<i>Staphylococcus aureus</i>	6 (1.86%)
<i>Enterococcus species</i>	12(3.72%)
Total	322(100%)

**Table.3** Etiological agents isolated from out patients

Bacterial species	Total number
<i>E.coli</i>	104(70.27%)
<i>Klebsiella</i>	44(29.72%)

<i>pneumoniae</i>	
Total	148(100%)

**Table.4** Susceptibility pattern of Gram negative isolates from hospitalized patients

<b>Antibiotic susceptibility (% sensitive)</b>								
<b>Organism</b>	Amp	Gen	AK	NIT	NX	CAZ	COT	I
<i>E.coli</i>	12	58	79	78	26	20	48	91
<i>Klebsiella pneumoniae</i>	-	60	73	33	50	18	44	89
<i>Pseudomonas aeruginosa</i>	-	63	90	-	41	42	-	100
<i>Acinetobacter species</i>	33	75	75	28	28	42	-	50
<i>Proteus mirabilis</i>	100	0	100	-	50	100	-	-
<i>Citrobacter species</i>	0	42	57	28	42	16	42	100

Amp –Ampicillin, Gen – Gentamicin,AK-Amikacin, NIT- Nitrofurantoin,NX –Norfloxacin, CAZ- Ceftazidime, COT-Cotrimoxazole,I-Imipenem.

**Table.5** Susceptibility pattern of Gram negative isolates from outpatients

<b>Antibiotic susceptibility (% sensitive)</b>								
<b>Organism</b>	Amp	Gen	AK	NIT	NX	CAZ	COT	I
<i>E.coli</i>	20	80	100	81	38	43	61	100
<i>Klebsiella pneumoniae</i>	-	82	100	36	90	50	60	100

Amp –Ampicillin, Gen – Gentamicin,AK-Amikacin, NIT- Nitrofurantoin,NX –Norfloxacin, CAZ- Ceftazidime, COT-Cotrimoxazole, I-Imipenem.

**Table.6** Susceptibility pattern of Gram positive isolates from hospitalized patients

<b>Organism</b>	<b>Amp</b>	<b>Gen</b>	<b>NIT</b>	<b>NX</b>	<b>COT</b>	<b>VA</b>
Enterococcus species	35	33	60	20	-	100
Staphylococcus aureus	25	50	100	50	100	100

Amp –Ampicillin, Gen – Gentamicin,AK-Amikaci NIT- Nitrofurantoin,NX –Norfloxacin, CAZ- Ceftazidime, COT- Cotrimoxazole, I-Imipenem.

Common etiological agent like *E.coli* had shown good susceptibility pattern to drugs

like Nitrofurantoin (78%,81%),Amikacin (79%,100%) and to Imipenem (91%,100%)

in hospitalized patients and out patients respectively.

Even etiological agents mainly implicated to cause only hospital acquired UTI like *Pseudomonas aeruginosa*, *Acinetobacter* species were more susceptible to Amikacin (90% & 75%), Imipenem (100% & 50%).

Among Gram positive isolates 75% of *Staphylococcus aureus* were MRSA and Beta lactam agents except 5<sup>th</sup> generation cephalosporins were of no use in treating these infections. In our study all isolates were sensitive to cotrimoxazole, Nitrofurantoin and Vancomycin.

The number of strains of *S.aureus* isolated in the present study was only six; more number of isolates needs to be tested in order to come to conclusion of susceptibility pattern of this species. *Enterococcus* strains showed 60% sensitivity to Nitrofurantoin, 35% sensitivity to ampicillin and 100% sensitive to Vancomycin.

As drug resistance among Gram negative bacilli and Gram positive cocci is increasing, most Gram negative uropathogens are resistant to commonly prescribed antibiotics by general practitioners like Norfloxacin (quinolones), beta lactams. Gram negative uropathogens are more susceptible to Nitrofurantoin, aminoglycosides like Amikacin, Cotrimoxazole (out patients) and Imipenem.

## References

Akram, M., Shahid, M., Khan, A.U. 2007. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in JNMC Hospital Aligarh, India. *Ann. Clin. Microbiol. Antimicrob.*, 23: 6–14.

Arjunan, M., Al-Salamah, A.A., Amuthan, M. 2010. Prevalence and antibiotics susceptibility of uropathogens in patients from a rural environment, Tamil Nadu. *Am. J. Infect. Dis.*, 6: 29–33.

Bhargavi, P.S., Gopala Rao, T.V., Mukkanti, K., Dinesh Kumar, B., Krishna, T.P. 2010. Increasing emergence of antibacterial resistance mainly in uropathogens: southeast part of India. *Int. J. Microbiol. Res.*, 2: 1–6.

Boyd, L.B., Atmar, R.L., Randall, G.L., Hamill, R.J., Steffen, D., Zechiedrich, L. 2008. Increased fluoroquinolone resistance with time in *Escherichia coli* from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. *BMC Infect. Dis.*, 8: 4–10.

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty fourth informational supplement. Clinical and Laboratory Standards Institute. M100-S24. CLSI, Wayne, PA.

Collee, J.G., Duguid, J.P., Fraser, A.G., Marmion, B.P., Simmons, A. 1999. Laboratory strategy in the diagnosis of infective syndromes. In: Collee, J.G., Fraser, A.G., Marmion, B.P., Simmons, A. (Eds). *Mackie & McCartney practical medical microbiology*, 14th edn. Churchill Livingstone, New York. Pp. 84–90.

Dalela, G., Gupta, S., Jain, D.K., Mehta, P. 2012. Antibiotic resistance pattern in uropathogens at a tertiary care hospital at Jhalawar with special reference to ESBL, AmpC  $\beta$ -lactamases and MRSA production. *J. Clin. Diagn. Res.*, 6: 645–651.

Ena, J., Amador, C., Martinez, C. 1995. 12. Ortiz de la Tabla V. Risk factors for

- acquisition of urinary tract infections caused by ciprofloxacin-resistant *Escherichia coli*. *J. Urol.*, 153: 117–20.
- Gatermann, S.G. 2007. Bacterial infections of the urinary tract. In: Borriello, P., Murray, P.R., Funke, G. (Eds). Topley & Wilson's microbiology & microbial infections, 10th edn, Vol. III. Hodder Arnold Publishers, London. Pp. 671–83.
- Gupta, N., Kundra, S., Sharma, A., Gautam, V., Arora, D.R. 2007. Antimicrobial susceptibility of uropathogens in India. *J. Infect. Dis. Antimicrob. Agents*, 24: 13–8.
- Kumar, M.S., Lakshmi, V., Rajagopalan, R. 2006. Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute. *Indian J. Med. Microbiol.*, 24(3): 208–11.
- Mandal, J., Srinivas Achaya, Buddhapriya, D., Subhash Chandra Parija. 2012. Antibiotic resistance pattern among common bacterial uropathogens with a special reference to ciprofloxacin resistant *Escherichia coli*. *Indian J. Med. Res.*, 136: 842–49.
- Manjunath, G.N., Prakash, R., Annam, V., Shetty, K. 2011. The changing trends in the spectrum of the antimicrobial drug resistance pattern of uropathogens which were isolated from hospitals and community patients with urinary tract infections in Tumkur and Bangalore. *Int. J. Biol. Med. Res.*, 2(2): 504–50.
- Mohanty, S., Kapil, A., Das, B.K., Dhawan, B. 2003. Antimicrobial resistance profile of nosocomial uropathogens in a tertiary care hospital. *Indian J. Med. Sci.*, 57: 148–54.
- Ram, S., Gupta, R., Gaheer, M. 2000. Emerging antibiotic resistance among the uropathogens. *Indian J. Med. Sci.*, 54: 388–94.
- Zervos, M.J., Hershberger, E., Nicolau, D.P., Ritchie, D.J., Blackner, L.K., Coyle, E.A., *et al.* 2003. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. *Clin. Infect. Dis.*, 37: 1643–8.